Exelixis, Inc. (NASDAQ:EXEL) Director Sue Gail Eckhardt Sells 18,838 Shares of Stock

Exelixis, Inc. (NASDAQ:EXEL) Director Sue Gail Eckhardt sold 18,838 shares of the stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $42.74, for a total transaction of $805,136.12. Following the completion of the transaction, the director now owns 21,380 shares in the company, valued at $913,781.20. This trade represents a 46.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Exelixis Stock Performance

EXEL stock opened at $42.22 on Thursday. The firm has a fifty day moving average price of $38.79 and a 200 day moving average price of $36.53. Exelixis, Inc. has a fifty-two week low of $21.36 and a fifty-two week high of $48.85. The firm has a market cap of $11.51 billion, a PE ratio of 23.85, a price-to-earnings-growth ratio of 1.13 and a beta of 0.28.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of EXEL. Coppell Advisory Solutions LLC purchased a new position in Exelixis during the fourth quarter worth $25,000. Hemington Wealth Management lifted its position in shares of Exelixis by 211.3% during the first quarter. Hemington Wealth Management now owns 769 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 522 shares during the last quarter. Colonial Trust Co SC lifted its position in shares of Exelixis by 616.9% during the fourth quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 765 shares during the last quarter. Principal Securities Inc. lifted its position in shares of Exelixis by 62.8% during the fourth quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 373 shares during the last quarter. Finally, Bartlett & CO. Wealth Management LLC bought a new stake in shares of Exelixis during the first quarter worth $37,000. 85.27% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on EXEL shares. Piper Sandler raised their target price on shares of Exelixis from $37.00 to $38.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 12th. UBS Group restated an “underperform” rating on shares of Exelixis in a research note on Thursday, April 17th. Guggenheim set a $45.00 target price on shares of Exelixis and gave the stock a “buy” rating in a research note on Thursday, May 15th. JMP Securities restated a “market outperform” rating and set a $41.00 target price on shares of Exelixis in a research note on Thursday, April 17th. Finally, Stephens restated an “equal weight” rating and set a $29.00 target price on shares of Exelixis in a research note on Wednesday, February 12th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $38.94.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.